$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Cholera - Pipeline Review, H1 2017
[Lowest Price Guaranteed: $2,000]

Published by Global Markets Direct: 28 Feb 2017 | 47388 | In Stock
Related Topics: Healthcare , Infectious Disease

Introduction

Cholera - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cholera - Pipeline Review, H1 2017, provides an overview of the Cholera (Infectious Disease) pipeline landscape.

Cholera is an acute infectious disease caused by a bacterium, Vibrio cholera, which results in a painless, watery diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as long as five days after infection. Often symptoms are mild. But sometimes they are very serious. Signs and symptoms of Cholera include rapid heart rate, loss of skin elasticity, low blood pressure, thirst, muscle cramps. If not treated, this can lead to shock and death in a matter of hours.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cholera - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cholera (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cholera (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cholera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 2 molecules, respectively.

Cholera (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cholera (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Cholera (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cholera (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cholera (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cholera (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cholera (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cholera (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Cholera - Pipeline Review, H1 2017

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Cholera - Overview

    Cholera - Therapeutics Development

    Pipeline Overview

    Pipeline by Companies

    Pipeline by Universities/Institutes

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Cholera - Therapeutics Assessment

    Assessment by Target

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Cholera - Companies Involved in Therapeutics Development

    Akthelia Pharmaceuticals Ltd

    Beijing Minhai Biotechnology Co Ltd

    MSD Wellcome Trust Hilleman Laboratories Pvt Ltd

    Napo Pharmaceuticals Inc

    Cholera - Drug Profiles

    AKT-10082 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    cholera (trivalent) vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    cholera (whole cell) vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    cholera [strain O1/El/Tor/Ogawa] vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    cholera vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Cholvax - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    crofelemer DR - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    gram-negative bacterial infections vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    IMSUTMR-1501 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules for Bacterial Infections - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Synthetic Peptides to Disrupt Cell Membrane for Bacterial and Fungal Infections - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Cholera - Dormant Projects

    Cholera - Discontinued Products

    Cholera - Product Development Milestones

    Featured News & Press Releases

    Apr 27, 2016: Hilleman Laboratories Provides Phase I/II Update on Cholera Vaccine

    Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

47388 | GMDHC8989IDB

Number of Pages

42

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Cholera - Pipeline Review, H2 2017
Cholera - Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcar...
18 Jul 2017 by Global Markets Direct USD $2,000 More Info
Cholera - Pipeline Insight, 2017
DelveInsight’s, “ Cholera -Pipeline Insights, 2017”, report provides comprehensive insights about pi...
10 Jul 2017 by Delve Insight USD $1,250 More Info
Cholera Global Clinical Trials Review, H1, 2017
Cholera Global Clinical Trials Review, H1, 2017SummaryGlobalData's clinical trial report, “Cholera G...
30 Jun 2017 by Global Data USD $2,500 More Info
Cholera-Pipeline Insights, 2017
DelveInsight’s, “ Cholera-Pipeline Insights, 2017”, report provides in depth insights on the pipelin...
30 May 2017 by Delve Insight USD $1,250 More Info
Cholera-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Cholera-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 20...
30 May 2017 by Delve Insight USD $2,000 More Info
Global Cholera Vaccine Market Research Report Forecast 2017 to 2021
The Global Cholera Vaccine Market Research Report Forecast 2017-2021 is a valuable source of insight...
15 May 2017 by S&P Consulting USD $2,800 More Info
Global Cholera Vaccines Market Research Report Forecast 2017 to 2021
The Global Cholera Vaccines Market Research Report Forecast 2017-2021 is a valuable source of insig...
10 May 2017 by S&P Consulting USD $2,800 More Info
Cholera Forecast for selected Asian Markets 2017-2027
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Cholera for Selected Asian Marke...
01 Jan 2017 by Black Swan Analysis USD $2,970 More Info
Cholera Global Clinical Trials Review, H2, 2016
Cholera Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Cholera G...
30 Nov 2016 by Global Data USD $2,500 More Info
Cholera Global Clinical Trials Review, H1, 2016
Cholera Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Cholera G...
29 Feb 2016 by Global Data USD $2,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Cholera - Pipeline Review, H1 2017 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...